2020
A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
Khan S, Zhao F, Solin L, Goldstein L, Cella D, Basik M, Golshan M, Julian T, Pockaj B, Lee C, Razaq W, Sparano J, Babiera G, Dy I, Jain S, Silverman P, Fisher C, Tevaarwerk A, Wagner L, Sledge G. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Journal Of Clinical Oncology 2020, 38: lba2-lba2. DOI: 10.1200/jco.2020.38.18_suppl.lba2.Peer-Reviewed Original ResearchOptimal systemic therapyIntact primary tumorEarly local therapyLocoregional treatmentRecurrence/progressionOverall survivalSystemic therapyLocal therapyBreast cancerDe novo stage IV breast cancerDe novo metastatic breast cancerFACT-B Trial Outcome IndexNovo metastatic breast cancerRandomized phase III trialStage IV breast cancerCox proportional hazards modelInitial systemic therapyLocal disease progressionLocoregional disease controlMonths post randomizationYear OS ratesStage IV diseaseStage IV patientsPhase 3 trialPhase III trials
2013
Management of the axilla II
Dominici L, Golshan M. Management of the axilla II. 2013, 441-446. DOI: 10.1201/b13937-44.Peer-Reviewed Original ResearchSystemic therapyBreast cancerTumor biologyIndividual patient's tumor biologyAdjuvant treatment recommendationsPatient's tumor biologyAxillary lymph nodesWhole breast irradiationPatients breast cancerNovel chemotherapeutic agentsEndocrine therapyLocal therapyLymph nodesTreatment recommendationsAromatase inhibitorsRadiation therapyLocal controlTherapyChemotherapeutic agentsAccelerated formsSame periodMethods of evaluationCancerBreast
2009
Surgical Complications and the Use of Neoadjuvant Bevacizumab.
Golshan M, Garber J, Gelman R, Tung N, Smith B, Troyan S, Greenberg C, Winer E, Ryan P. Surgical Complications and the Use of Neoadjuvant Bevacizumab. Cancer Research 2009, 69: 43-43. DOI: 10.1158/0008-5472.sabcs-09-43.Peer-Reviewed Original ResearchTriple-negative breast cancerDefinitive local therapyPhase II trialPostoperative complicationsNeoadjuvant cisplatinDefinitive surgeryII trialWound breakdownLocal therapyMedian ageBreast cancerSingle-arm phase II trialArm phase II trialTwo-sided Fisher's exact testClinical stage IIDose-dense ACSafety of bevacizumabOperable breast cancerBreast cancer surgerySingle-arm trialNegative breast cancerFisher's exact testCycles cisplatinNeoadjuvant bevacizumabNeoadjuvant setting